{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:44:15Z","timestamp":1793969055844,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T00:00:00Z","timestamp":1452211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T00:00:00Z","timestamp":1452211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A meta-analysis was conducted to assess the clinical efficacy and safety of dulaglutide in patients with type 2 diabetes mellitus (T2DM). Medline, Embase, Cochrane Library and www. clinicaltrials. gov (up to February 15<jats:sup>th<\/jats:sup>, 2015) were searched. Randomized controlled trials comparing dulaglutide to other drugs for T2DM were collected. Twelve RCTs were included and the overall bias was low. As the monotherapy, compared with control (placebo, metformin and liraglutide), dulaglutide resulted in a significant reduction in HbA1c (WMD, \u22120.68%; 95% CI, \u22120.95 to \u22120.40), FPG (WMD, \u22120.90\u2009mmol\/L; 95% CI, \u22121.28 to \u22120.52), a similar risk of hypoglycemia (7.8% vs. 10.6%), less body weight loss (WMD, 0.51\u2009kg; 95% CI, 0.27 to 0.75). As an add-on intervention with oral antihyperglycemic medication (OAM) and insulin, compared with control (placebo, sitagliptin, exenatide, liraglutide and glargine), dulaglutide lowered HbA1c (WMD, \u22120.51%; 95% CI, \u22120.68 to \u22120.35) and body weight significantly (WMD, \u22121.30\u2009kg, 95% CI, \u22121.85 to \u22121.02) notably and elicited a similar reduction in FPG (WMD, \u22120.19\u2009mmol\/L; 95% CI, \u22121.20 to 0.82), an similar incidence of hypoglycemia (24.5% vs. 24.5%). This meta-analysis revealed the use of dulaglutide as a monotherapy or an add-on to OAM and lispro appeared to be effective and safe for adults with T2DM.<\/jats:p>","DOI":"10.1038\/srep18904","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T11:11:27Z","timestamp":1452251487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review"],"prefix":"10.1038","volume":"6","author":[{"given":"Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanwei","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,8]]},"reference":[{"key":"BFsrep18904_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","volume":"297","author":"JJ Holst","year":"2009","unstructured":"Holst, J. J., Vilsb\u00f8ll, T. & Deacon, C. F. The incretin system and its role in type 2 diabetes mellitus. Molecular and cellular endocrinology 297, 127\u2013136 (2009).","journal-title":"Molecular and cellular endocrinology"},{"key":"BFsrep18904_CR2","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1089\/dia.2012.0098.edw","volume":"14","author":"KL Edwards","year":"2012","unstructured":"Edwards, K. L., Stapleton, M., Weis, J. & Irons, B. K. An update in incretin-based therapy: A focus on glucagon-like peptide-1 receptor agonists. Diabetes technology & therapeutic 14, 951\u2013967 (2012).","journal-title":"Diabetes technology & therapeutic"},{"key":"BFsrep18904_CR3","doi-asserted-by":"publisher","first-page":"e47936","DOI":"10.1371\/journal.pone.0047936","volume":"7","author":"N Li","year":"2012","unstructured":"Li, N., Lu, J. & Willars, G. B. Allosteric modulation of the activity of the glucagon-like peptide-1 (glp-1) metabolite glp-1 9-36 amide at the glp-1 receptor. PloS one 7, e47936 (2012).","journal-title":"PloS one"},{"key":"BFsrep18904_CR4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier, J. J. Glp-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature review. Endocrinology 8, 728\u2013742 (2012).","journal-title":"Nature review. Endocrinology"},{"key":"BFsrep18904_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/dmrr.1080","volume":"26","author":"W Glaesner","year":"2010","unstructured":"Glaesner, W. et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue ly2189265, an fc fusion protein. Diabetes\/metabolism research and reviews 26, 287\u2013296 (2010).","journal-title":"Diabetes\/metabolism research and reviews"},{"key":"BFsrep18904_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1463-1326.2011.01365.x","volume":"13","author":"P Barrington","year":"2011","unstructured":"Barrington, P. et al. Ly2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes, obesity & metabolism 13, 434\u2013438 (2011).","journal-title":"Diabetes, obesity & metabolism"},{"key":"BFsrep18904_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1463-1326.2011.01364.x","volume":"13","author":"P Barrington","year":"2011","unstructured":"Barrington, P. et al. A 5-week study of the pharmacokinetics and pharmacodynamics of ly2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes, obesity & metabolism 13, 426\u2013433 (2011).","journal-title":"Diabetes, obesity & metabolism"},{"key":"BFsrep18904_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1463-1326.2011.01366.x","volume":"13","author":"GE Umpierrez","year":"2011","unstructured":"Umpierrez, G. E. et al. The effects of ly2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight\/obese patients with type 2 diabetes: The ego study. Diabetes, obesity & metabolism 13, 418\u2013425 (2011).","journal-title":"Diabetes, obesity & metabolism"},{"key":"BFsrep18904_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/j.1464-5491.2012.03745.x","volume":"29","author":"G Grunberger","year":"2012","unstructured":"Grunberger, G. et al. Monotherapy with the once-weekly glp-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: Dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabetic medicine 29, 1260\u20131267 (2012).","journal-title":"Diabetic medicine"},{"key":"BFsrep18904_CR10","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.jcjd.2013.08.129","volume":"37","author":"B Guerci","year":"2013","unstructured":"Guerci, B. et al. Safety and efficacy of dulaglutide versus sitagliptin after 104 weeks in type 2 diabetes (award-5). Canadian journal of diabetes 37, S44\u201345 (2013).","journal-title":"Canadian journal of diabetes"},{"key":"BFsrep18904_CR11","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2337\/dc13-2761","volume":"37","author":"M Nauck","year":"2014","unstructured":"Nauck, M. et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (award-5). Diabetes care 37, 2149\u20132158 (2014).","journal-title":"Diabetes care"},{"key":"BFsrep18904_CR12","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2337\/dc13-2759","volume":"37","author":"G Umpierrez","year":"2014","unstructured":"Umpierrez, G., Tof\u00e9 Povedano, S., P\u00e9rez Manghi, F., Shurzinske, L. & Pechtner, V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (award-3). Diabetes care 37, 2168\u20132176 (2014).","journal-title":"Diabetes care"},{"key":"BFsrep18904_CR13","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2337\/dc13-2760","volume":"37","author":"C Wysham","year":"2014","unstructured":"Wysham, C. et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (award-1). Diabetes care 37, 2159\u20132167 (2014).","journal-title":"Diabetes care"},{"key":"BFsrep18904_CR14","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","volume":"384","author":"KM Dungan","year":"2014","unstructured":"Dungan, K. M. et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (award-6): A randomised, open-label, phase 3, non-inferiority trial. Lancet 384, 1349\u20131357 (2014).","journal-title":"Lancet"},{"key":"BFsrep18904_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1507\/endocrj.EJ14-0147","volume":"64","author":"Y Terauchi","year":"2014","unstructured":"Terauchi, Y., Satoi, Y., Takeuchi, M. & Imaoka, T. Monotherapy with the once weekly glp-1 receptor agonist dulaglutide for 12 weeks in japanese patients with type 2 diabetes: Dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocrine journal 64, 949\u2013959 (2014).","journal-title":"Endocrine journal"},{"key":"BFsrep18904_CR16","unstructured":"Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (award-2). Clinicaltrials.gov. (2015). Available at: www.clinicaltrials.gov. (Accessed: 15 February, 2015)."},{"key":"BFsrep18904_CR17","unstructured":"Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (award-4). Clinicaltrials.gov. (2014). Available at: www.clinicaltrials.gov. (Accessed: 15 February, 2015)."},{"key":"BFsrep18904_CR18","unstructured":"Eli Lilly and Company. A study of dulaglutide in japanese participants with type 2 diabetes mellitus. Clinicaltrials.gov. (2012). Available at: www.clinicaltrials.gov. (Accessed: 15 February, 2015)."},{"key":"BFsrep18904_CR19","unstructured":"Eli Lilly and Company. A study of ly2189265 in japanese participants with type 2 diabetes mellitus. Clinicaltrials.gov. (2014). Available at: www.clinicaltrials.gov. (Accessed: 15 February, 2015)."},{"key":"BFsrep18904_CR20","doi-asserted-by":"crossref","unstructured":"Workgroup on Hypoglycemia ADA. Defining and reporting hypoglycemia in diabetes: A report from the american diabetes association workgroup on hypoglycemia. Diabetes care 28, 1245\u20131249 (2005).","DOI":"10.2337\/diacare.28.5.1245"},{"key":"BFsrep18904_CR21","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1530\/EJE-09-0101","volume":"160","author":"M Monami","year":"2009","unstructured":"Monami, M., Marchionni, N. & Mannucci, E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-analysis of randomized clinical trials. European journal of endocrinology 160, 909\u2013917 (2009).","journal-title":"European journal of endocrinology"},{"key":"BFsrep18904_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1472-6823-10-20","volume":"10","author":"DS Shyangdan","year":"2010","unstructured":"Shyangdan, D. S., Royle, P. L., Clar, C., Sharma, P. & Waugh, N. R. Glucagon-like peptide analogues for type 2 diabetes mellitus: Systematic review and meta-analysis. BMC endocrine disorders 10, 20 (2010).","journal-title":"BMC endocrine disorders"},{"key":"BFsrep18904_CR23","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1185\/03007995.2011.590127","volume":"27","author":"K Esposito","year":"2011","unstructured":"Esposito, K. et al. Glp-1 receptor agonists and hba1c target of &lt;7% in type 2 diabetes: Meta-analysis of randomized controlled trials. Current medical research and opinion 27, 1519\u20131528 (2011).","journal-title":"Current medical research and opinion"},{"key":"BFsrep18904_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00592-014-0644-5","volume":"52","author":"M Cotugno","year":"2015","unstructured":"Cotugno, M. et al. Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: A 12-month retrospective evaluation. Acta diabetologica 52, 331\u2013336 (2015).","journal-title":"Acta diabetologica"},{"key":"BFsrep18904_CR25","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1161\/01.CIR.0000017823.53114.4C","volume":"105","author":"RH Eckel","year":"2002","unstructured":"Eckel, R. H., Barouch, W. W. & Ershow, A. G. Report of the national heart, lung and blood institute-national institute of diabetes and digestive and kidney diseases working group on the pathophysiology of obesity-associated cardiovascular disease. Circulation 105, 2923\u20132928 (2002).","journal-title":"Circulation"},{"key":"BFsrep18904_CR26","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/dmrr.2548","volume":"30","author":"D Raccah","year":"2014","unstructured":"Raccah, D., Gourdy, P., Sagnard, L. & Ceriello, A. Lixisenatide as add-on to oral antidiabetic therapy: An effective treatment for glycemic control with body weight benefits in type 2 diabetes. Diabetes\/metabolism research and reviews 30, 742\u2013748 (2014).","journal-title":"Diabetes\/metabolism research and reviews"},{"key":"BFsrep18904_CR27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup, A. et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human glp-1 analog, liraglutide. International journal of obesity 36, 843\u2013854 (2012).","journal-title":"International journal of obesity"},{"key":"BFsrep18904_CR28","first-page":"672658","volume":"2012","author":"M Monami","year":"2012","unstructured":"Monami, M., Dicembrini, I., Marchionni, N., Rotella, C. M. & Mannucci, E. Effects of glucagon-like peptide-1 receptor agonists on body weight: A meta-analysis. Experimental diabetes research 2012, 672658 (2012).","journal-title":"Experimental diabetes research"},{"key":"BFsrep18904_CR29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/j.1742-1241.2012.03006.x","volume":"66","author":"R Pencek","year":"2012","unstructured":"Pencek, R., Blickensderfer, A., Li, Y., Brunell, S. C. & Chen, S. Exenatide once weekly for the treatment of type 2 diabetes: Effectiveness and tolerability in patient subpopulations. International journal of clinical practice 66, 1021\u20131032 (2012).","journal-title":"International journal of clinical practice"},{"key":"BFsrep18904_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18433\/J3G883","volume":"15","author":"S Nikfar","year":"2012","unstructured":"Nikfar, S., Abdollahi, M. & Salari, P. The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials. Journal of pharmacy & pharmaceutical sciences 15, 1\u201330 (2012).","journal-title":"Journal of pharmacy & pharmaceutical sciences"},{"key":"BFsrep18904_CR31","doi-asserted-by":"publisher","first-page":"230624","DOI":"10.1155\/2012\/230624","volume":"2012","author":"F Sun","year":"2012","unstructured":"Sun, F. et al. Impact of glp-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: A mixed treatment comparison meta-analysis. Experimental diabetes research 2012, 230624 (2012).","journal-title":"Experimental diabetes research"},{"key":"BFsrep18904_CR32","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.2337\/dc12-2504","volume":"36","author":"MA Nauck","year":"2013","unstructured":"Nauck, M. A. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes care 36, 2126\u20132132 (2013).","journal-title":"Diabetes care"},{"key":"BFsrep18904_CR33","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.2337\/dc12-2713","volume":"36","author":"PC Butler","year":"2013","unstructured":"Butler, P. C., Elashoff, M., Elashoff, R. & Gale, E. A. A critical analysis of the clinical use of incretin-based therapies: Are the glp-1 therapies safe? Diabetes care 36, 2118\u20132125 (2013).","journal-title":"Diabetes care"},{"key":"BFsrep18904_CR34","doi-asserted-by":"publisher","first-page":"g2366","DOI":"10.1136\/bmj.g2366","volume":"348","author":"L Li","year":"2014","unstructured":"Li, L. et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: Systematic review and meta-analysis of randomised and non-randomised studies. Bmj. 348, g2366 (2014).","journal-title":"Bmj."},{"key":"BFsrep18904_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.diabres.2014.01.010","volume":"103","author":"M Monami","year":"2014","unstructured":"Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I. & Mannucci, E. Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Diabetes research and clinical practice. 103, 269\u2013275 (2014).","journal-title":"Diabetes research and clinical practice."},{"key":"BFsrep18904_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12325-014-0098-8","volume":"31","author":"M DeKoven","year":"2014","unstructured":"DeKoven, M., Lee, W. C., Bouchard, J., Massoudi, M. & Langer, J. Real-world cost-effectiveness: Lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Advances in therapy. 31, 202\u2013216 (2014).","journal-title":"Advances in therapy."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep18904.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18904","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18904.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:34:40Z","timestamp":1672900480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep18904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,5,10]]}},"alternative-id":["BFsrep18904"],"URL":"https:\/\/doi.org\/10.1038\/srep18904","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,8]]},"assertion":[{"value":"7 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18904"}}